Should Investors Sell Eli Lilly After This Recent Regulatory News?

It's no secret that the broader stock market has been under pressure lately, but many of its issues have to do with marketwide worries, including impending interest-rate hikes in the U.S. However, some companies are facing headwinds of their own that could lead to even more losses in the coming weeks.

Let's look at a healthcare company that recently got bad news from regulators: Eli Lilly (NYSE: LLY). This drugmaker fell along with the market in recent months, and it could continue to be vulnerable in the short term following recent developments.

Source Fool.com